InvivydIVVD
About: Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
Employees: 95
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
20,275% more call options, than puts
Call options by funds: $815K | Put options by funds: $4K
50% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
2.11% less ownership
Funds ownership: 65.78% [Q1] → 63.67% (-2.11%) [Q2]
7% less funds holding
Funds holding: 86 [Q1] → 80 (-6) [Q2]
21% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 29
74% less capital invested
Capital invested by funds: $321M [Q1] → $83.5M (-$238M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Patrick Trucchio 38% 1-year accuracy 38 / 101 met price target | 1,329%upside $15 | Buy Reiterated | 3 Sept 2024 |
HC Wainwright & Co. Patrick Trucchio 38% 1-year accuracy 38 / 101 met price target | 1,329%upside $15 | Buy Reiterated | 30 Aug 2024 |
HC Wainwright & Co. Patrick Trucchio 38% 1-year accuracy 38 / 101 met price target | 1,329%upside $15 | Buy Reiterated | 27 Aug 2024 |
Financial journalist opinion
Based on 3 articles about IVVD published over the past 30 days